Matrix metalloproteinase-9 is upregulated in nucleophosmin-anaplastic lymphoma kinase-positive anaplastic lymphomas and activated at the cell surface by the chaperone heat shock protein 90 to promote cell invasion

Cancer Research

Volumn 70, Issue 17, 2010, Pages 6978-6987

  Lagarrigue, Frédéric ^a   Dupuis Coronas, Sophie ^a   Ramel, Damien ^a   Delsol, Georges ^a   Tronchère, Hélène ^a   Payrastre, Bernard ^a   Gaits Iacovoni, Frédérique ^a  

^a France   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; ENZYME ANTIBODY; GELATINASE B; HEAT SHOCK PROTEIN 90; HERMES ANTIGEN; ILOMASTAT; NUCLEOPHOSMIN; RAC1 PROTEIN; CD44 PROTEIN, HUMAN; DIPEPTIDE; ENZYME PRECURSOR; MATRIX METALLOPROTEINASE INHIBITOR; N-(2(R)-2-(HYDROXAMIDOCARBONYLMETHYL)-4-METHYLPENTANOYL)-L-TRYPTOPHAN METHYLAMIDE; P80(NPM-ALK) PROTEIN; PRO-MATRIX METALLOPROTEINASE 9; PROTEIN TYROSINE KINASE; RAC1 PROTEIN, HUMAN;

ARTICLE; CELL INVASION; CELL SURFACE; COMPLEX FORMATION; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME RELEASE; HUMAN; HUMAN TISSUE; LARGE CELL LYMPHOMA; LYMPH NODE BIOPSY; MOLECULAR DOCKING; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN PROTEIN INTERACTION; UPREGULATION; BIOSYNTHESIS; CELL MEMBRANE; GENETICS; METABOLISM; PATHOLOGY; TUMOR CELL LINE; TUMOR INVASION;

ANTIGENS, CD44; CELL LINE, TUMOR; CELL MEMBRANE; DIPEPTIDES; ENZYME ACTIVATION; ENZYME PRECURSORS; HSP90 HEAT-SHOCK PROTEINS; HUMANS; LYMPHOMA, LARGE-CELL, ANAPLASTIC; MATRIX METALLOPROTEINASE 9; MATRIX METALLOPROTEINASE INHIBITORS; NEOPLASM INVASIVENESS; PROTEIN-TYROSINE KINASES; RAC1 GTP-BINDING PROTEIN; UP-REGULATION;

EID: 77956294299     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-10-0861     Document Type: Article

References (44)

1. Lamant L, Meggetto F, al Saati T, et al. High incidence of the t(2;5) (p23;q35) translocation in anaplastic large cell lymphoma and its lack of detection in Hodgkin's disease. Comparison of cytogenetic analysis, reverse transcriptase-polymerase chain reaction, and P-80 immunostaining. Blood 1996;87:284-91.
2. Turner SD, Alexander DR. What have we learnt from mouse models of NPM-ALK-induced lymphomagenesis? Leukemia 2005;20:572-82.
3. Cussac D, Pichereaux C, Colomba A, et al. Proteomic analysis of anaplastic lymphoma cell lines: identification of potential tumour markers. Proteomics 2006;6:3210-22.
4. Crockett DK, Lin Z, Elenitoba-Johnson KS, Lim MS. Identification of NPM-ALK interacting proteins by tandem mass spectrometry. Oncogene 2004;23:2617-29.
5. Chiarle R, Voena C, Ambrogio C, Piva R, Inghirami G. The anaplastic lymphoma kinase in the pathogenesis of cancer. Nat Rev Cancer 2008;8:11-23.
6. + anaplastic large-cell lymphoma. Blood 2007;110:2259-67.
7. Ambrogio C, Voena C, Manazza AD, et al. p130Cas mediates the transforming properties of the anaplastic lymphoma kinase. Blood 2005;106:3907-16.
8. Colomba A, Courilleau D, Ramel D, et al. Activation of Rac1 and the exchange factor Vav3 are involved in NPM-ALK signaling in anaplastic large cell lymphomas. Oncogene 2008;27:2728-36.
9. Armstrong F, Duplantier MM, Trempat P, et al. Differential effects of X-ALK fusion proteins on proliferation, transformation, and invasion properties of NIH3T3 cells. Oncogene 2004;23:6071-82.
10. Cussac D, Greenland C, Roche S, et al. Nucleophosmin-anaplastic lymphoma kinase of anaplastic large-cell lymphoma recruits, activates, and uses pp60c-src to mediate its mitogenicity. Blood 2004; 103:1464-71.
11. Sahai E, Marshall CJ. RHO-GTPases and cancer. Nat Rev Cancer 2002;2:133-42.
12. Stamenkovic I. Extracellular matrix remodelling: the role of matrix metalloproteinases. J Pathol 2003;200:448-64.
13. McCawley LJ, Matrisian LM. Matrix metalloproteinases: they're not for matrix anymore!. Curr Opin Cell Biol 2001;13:534-40.
14. Björklund M, Koivunen E. Gelatinase-mediated migration and invasion of cancer cells. Biochim Biophys Acta 2005;1755:37-69.
15. Monferran S, Paupert J, Dauvillier S, Salles B, Muller C. The membrane form of the DNA repair protein Ku interacts at the cell surface with metalloproteinase 9. EMBO J 2004;23:3758-68.
16. 1 Integrin and 190-kDa CD44v constitute a cell surface docking complex for gelatinase B/MMP-9 in chronic leukemic but not normal B cells. Blood 2008;112:169-78.
17. Paupert J, Mansat-De Mas V, Demur C, Salles B, Muller C. Cell-surface MMP-9 regulates the invasive capacity of leukemia blast cells with monocytic features. Cell Cycle 2008;7:1047-53.
18. Egebald M, Werb Z. New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2002;2:161-74.
19. Kossakowska AE, Edwards DR, Prusinkiewicz C, Zhang MC, Guo D, Urbanski SJ. Interleukine-6 regulation of matrix mettalloproteinase (MMP-2 and MMP-9) and tissue inhibitors of metalloproteinase (TIMP-1) expression in malignant non-Hodgkin's lymphomas. Blood 1999;94:2080-89.
20. Bauvois B, Dumont J, Mathiot C, Kolb JP. Production of matrix metalloproteinase-9 in early stage B-CLL: suppression by interferons. Leukemia 2002;16:791-98.
21. Poyer F, Coquerel B, Pegahi R, et al. Secretion of MMP-2 and MMP- 9 induced VEGF autocrine loop correlates with clinical features in childhood acute lymphoblastic leukemia. Leuk Res 2009;33:407-17.
22. Lamant L, Espinos E, Duplantier M, et al. Establishment of a novel anaplastic large-cell lymphoma-cell line (COST) from a "small-cell variant" of ALCL. Leukemia 2004;18:1693-98.
23. Honorat JF, Ragab A, Lamant L, Delsol G, Ragab-Thomas J. SHP1 tyrosine phosphatase negatively regulates NPM-ALK tyrosine kinase signaling. Blood 2006;107:4130-38.
24. Bowden ET, Coopman PJ, Mueller SC. Invadopodia: unique methods for measurement of extracellular matrix degradation in vitro. Methods Cell Biol 2001;63:613-27.
25. Rust R, Blokzijl T, Harms G, et al. TIMP-1 expression in anaplastic large cell lymphoma is usually restricted to macrophages and only seldom observed in tumoral cells. J Pathol 2005;206:445-50.
26. Delsol G, Ralfkiaer E, Stein H, Wright D, Jaffe ES. Anaplastic large cell lymphomas. In: Jaffe ES, Harris NL, Stein H, Vardiman JW, editors. World health Organization classification of tumors: pathology and genetics of tumors of haematopoietic and lymphoid tissues. Lyon: IARC; 2001, p. 230-35.
27. Yu A, Stamenkovic I. Localization of matrix metalloproteinase 9 to the cell surface provides a mechanism for CD44-mediated tumor invasion. Genes Dev 1999;13:35-48.
28. Linder S. The matrix corroded: podosomes and invadopodia in extracellular matrix degradation. Trends Cell Biol 2007;17:107-17.
29. Gao Y, Dickerson JB, Guo F, Zheng J, Zheng Y. Rational design and characterization of a Rac GTPase-specific small molecule inhibitor. Proc Natl Acad Sci U S A 2004;101:7618-23.
30. Eustace BD, Sakurai T, Stewart JK, et al. Functional proteomic screens reveal an essential extracellular role for hsp90α in cancer cell invasiveness. Nat Cell Biol 2004;6:507-14.
31. Bonvini P, Gastaldi T, Falini B, Rosolen A. Nucleophosmin-anaplastic lymphoma kinase (NPM-ALK), a novel Hsp90-client tyrosine kinase: down-regulation of NPM-ALK expression and tyrosine phosphorylation in ALK(+) CD30(+) lymphoma cells by the Hsp90 antagonist 17-allylamino,17-demethoxygeldanamycin. Cancer Res 2002;62: 1559-66.
32. Kamal A, Thao L, Sensintaffar J, et al. A high-affinity conformation of hsp90 confers tumour selectivity on Hsp90 inhibitors. Nature 2003; 425:407-10.
33. Deryugina EI, Quigley JP. Matrix metalloproteinases and tumor metastasis. Cancer Metastasis Rev 2006;25:9-34.
34. Stetler-Stevenson M, Mansoor A, Lim M, et al. Expression of matrix metalloproteinases and tissue inhibitors of metalloproteinases in reactive and neoplastic lymphoid cells. Blood 1997;89:1708-15.
35. 1 integrin or CXCR4 engagement via distinct pathways, localizes to podosomes, and is involved in cell invasion and migration. Blood 2006;108:3143-51.
36. Kamiguti AS, Lee ES, Till KJ, et al. The role of matrix metalloproteinase 9 in the pathogenesis of chronic lymphocytic leukaemia. Br J Haematol 2004;125:128-40.
37. Pals ST, Horst E, Ossekoppele GJ, Figdor CG, Scheper RJ, Meijer CJLM. Expression of lymphocyte homing receptor as a mechanism of dissemination in non-Hodgkin's lymphoma. Blood 1989; 73:885-88.
38. Horst E, Meijer CJ, Radaszkiewicz T, Ossekoppele GJ, Van Krieken JH, Pals ST. Adhesion molecules in the prognosis of diffuse large-cell lymphoma: expression of a lymphocyte homing receptor (CD44), LFA-1 (CD11a/18), and ICAM-1 (CD54). Leukemia 1990;4:595-99.
39. Yu Q, Stamenkovic I. Cell surface-localized matrix metalloproteinase- 9 proteolytically activates TGF-β and promotes tumor invasion and angiogenesis. Genes Dev 2000;14:163-76.
40. Ambrogio C, Voena C, Manazza AD, et al. The anaplastic lymphoma kinase controls cell shape and growth of anaplastic large cell lymphoma through Cdc42 activation. Cancer Res 2008;68: 8899-907.
41. Lozano E, Betson M, Braga VM. Tumor progression: small GTPases and loss of cell-cell adhesion. BioEssays 2003;25:452-63.
42. Etienne-Maneville S, Hall A. Rho GTPases in cell biology. Nature 2002;420:629-35.
43. Whitesell L, Lindquist SL. HSP90 and the chaperoning of cancer. Nat Rev Cancer 2005;5:761-72.
44. Yang Y, Rao R, Shen J, et al. Role of acetylation and extracellular location of heat shock protein 90aα in tumor cell invasion. Cancer Res 2008;68:4833-42.